bipolar therapy prostate cancer

Samuel Denmeade, MD, of Johns Hopkins University School of Medicine, highlights his research on blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial. This research was presented as a late-breaking abstract at the 2024...

Reversing the effects of androgen deprivation therapy in men with metastatic castration resistant prostate cancer Abstract Background: Bipolar androgen therapy (BAT) is the cyclic administration of high dose testosterone as a novel treatment for metastatic castration resistant prostate cancer...